Use evidence -based research to clearly explain the effect of traditional Chinese medicine

On July 6, the Management Committee of Shijiazhuang High -tech Industrial Development Zone, Hebei Pharmaceutical Association, Hebei Provincial Pharmaceutical Industry Association, and World Chinese Medicine Association Joint Society of Medicine Corporation and other joint sponsored "The Summit Forum" and the Innovation Achievement Transformation Forum was held. Zhang Boyi, Cong Bin, Zhang Yun, Yang Baofeng, Yu Jinming, Tian Jinzhou, Wu Yiling and other academicians, as well as Li Yigui, a master of Chinese medicine, and well -known experts and scholars from the Chinese medicine industry from all over the country gathered through the way The important achievements of theoretical inheritance, innovation, and transformation have conducted in -depth exchanges. In the summit forum, Dean Jia Zhenhua, the Institute of Traditional Chinese and Western Medicine Medical Research Institute of Hebei Province, made an academic report entitled "30 Years of Evidence -based Road and Chinese Medicine Inheritance Innovation". The advantages and the major incidents of evidence -based research on Tongluo Drugs have been pointed out in the past 30 years. It is pointed out that the efficacy of the use of Chinese medicine with science is an important task of inheriting, developing well, and using traditional Chinese medicine.

Evidence -based medicine is the international gold standard for testing efficacy

Evidence -based medicine research can be described as a new milestone in the history of modern medicine. The concept of evidence -based medicine originated in the 1980s. In 1992, Jama published a comprehensive explanation of evidence -based medicine in the evidence -based medical group. After 30 years of development, the concept of evidence -based medicine has become popular, and clinical practice is always guided. Evidence -based medicine transforms medical models from experience to scientific evidence. There are many evidence of evidence -based medicine. Random control test (RCT) has become the main method of evaluating drugs in the world, and it is also an important basis for the formulation of authoritative guidelines.

The conclusions of evidence -based medical research, as the main basis for clinical guidelines and consensus formulation, are considered evidence of drug use that is truly worthy of doctors and patients. It is an internationally recognized "gold standard" of scientific and scientific evaluation of drugs.

Evidence -based medical evidence is the key to explain and clear the effect of traditional Chinese medicine

Dean Jia Zhenhua pointed out in the report that the two thousand years of development history of the Discipline of Traditional Chinese Medicine demonstrated its own laws: "The main line of academic development, combining theory and clinical clinical, inseparable from medicine and pharmaceuticals, and promoting development."

Taking Ling Pharmaceutical has been practicing the development law of traditional Chinese medicine, adherence to clinical practice, guidance of theoretical hypotheng, based on the treatment of prescriptions, and based on clinical efficacy Under the guidance of the theoretical of neat disease, promote the research and development of innovative drugs. At the same time, the efficacy of modern evidence -based research and verifying drugs is used to clear the efficacy of traditional Chinese medicine in modern medical language, and obtain the recognition of the public and even the world. Dean Jia emphasized that "the world must accept traditional medicine with open minds, and traditional medicine must be widely accepted to depend on the affirmation of curative effect. The key link is the scientific nature of the research method." Organic combination of evidence -based medicine with the characteristics of traditional Chinese medicine and clinical practice can not only greatly improve the level of clinical diagnosis and treatment, but also provides stage and opportunities for Chinese medicine to prove its own medical value and provide stage and opportunities in the world science system.

According to the data of the "China Clinical Test Registration Center" and "Clinicaltrics.gov", the data of the registration platform showed that Ling Pharmaceutical carried out a total of 33 evidence -based medical research since 1995, using large -scale, diversity, random, double -blindness The control method to test the efficacy and safety of the drug. At present, more than 20 items have been completed, and all have achieved good test results.

In 2008, "Ginseng Yangxin Capsule Capsule Treatment of Cleelin Heart Extreme Clinical Research (National 973 Project)" and "Ginseng Yangxin Capsule Capsule therapy for non -organic arrhythmia (National 973 Project)" was from Nanjing Medical University 32 hospitals and other hospitals were completed. The results showed that ginseng Yang Xinxin Capsule therapy had no structural cardiac woses of 74.2%, which was better than the placebo control group. , A significant improvement of clinical symptoms such as palpitations, fatigue, insomnia and other patients with early improvement rooms. The research paper was published in the "Chinese Medical Journal".

In 2008, Ginseng Yangxin Capsule was treated with slow arrhythmia and effective clinical research (National 973 project) led by Fuwai Hospital of the Chinese Academy of Medical Sciences. The efficiency is significantly better than the control group. The research papers were published in the well -known international journal "Evidence -based Supplement and Alternative Medicine", with the influencing factor of 2.63.

The "Ginseng Yangxin Capsule Capsule therapy for paroxysmal atrial fibrillation and effective clinical research (National 973 Project)" carried out in 2008 was led by Beijing Chaoyang Hospital. Symptoms are better than Protoone. The research paper was published in the "Chinese Medical Journal".

In 2009, the "Tongxinluo improved acute myocardial infarction PCI without any rear random, double blindness, placebo control, multi -center clinical research (National 973 Project)" was completed by 9 three hospitals including Fuwai Hospital of the Chinese Academy of Medical Sciences. The results show that Tongxinluo capsules can significantly improve the coronary veins of patients with acute myocardial infarction after the treatment of myocardial muscle reinfusion, which has a significant prevention effect on the myocardial muscle after the acute myocardial infarction intervention. The research paper was published in the "Chinese Medical Journal".

In 2012, the "Qiji Qiangxin Capsule treatment of chronic heart failure and safety random, double -blindness, placebo control, multi -center clinical research (National 973 Project)" was by 23 triads including Nanjing Medical University First Affiliated Hospital The hospital was completed, and the results showed that: Qiqiang Qiang Heart Capsule significantly reduced the level of serum NT-PROBNP in patients with chronic heart failure, a decrease of greater than 30%and the absolute value of the decline was better than the control group; significantly improved the quality of life of patients with chronic heart failure than the control of the control. Group; significantly improve the heart function of patients with chronic heart failure (NYHA heart function classification) better than the control group; significantly improve the left ventricular ejection score (LVEF) in patients with chronic heart failure than the control group; The control group; significantly reduced the incidence of compound endpoints than the control group. The research papers were published in the world -renowned journal "American Heart Society Magazine". The impact factor of the periodical period was 24.093. "Ginseng Yangxin Heart Capsule Treatment Light and Medium -shrinkable Heart Function was randomly random, double -blindness, double blindness, double blindness, double blindness, The placebo control, multi -center clinical research (National 973 project) "was completed by 30 three -sectors including Wuhan University People's Hospital. The results show that it significantly reduces ventricular premature beats; improves heart function. The research paper was published in the "Chinese Medical Journal".

In 2014, the "Ginseng Yangxin Capsule Capsule Treatment Sinic Combat Police, Double Blind, Place Control, Multi -Center Clinical Research (National 973 Project)" was jointly carried out by 30 three hospitals including Nanjing Medical University First Affiliated Hospital. The results showed that reducing ventricular premature beats; improving ventricular rates; improving clinical symptoms. The research papers were published in the well -known international journal "Evidence -based Supplement and Alternative Medicine".

The "Tongxinluo intervention intervention in the cervical plaque, double -blindness, placebo control, multi -center clinical research (national 973 project)" carried out in 2014 was completed by Shandong University Qilu Hospital and 35 three -level hospitals across the country. : Tongxinluo can delay the progress of the cervical arterial IMT, plaque area, and vascular reconstruction index (the proportion of patients with IMT decreases by 38.5%), significantly reduces the first cardiovascular incident in patients with atherosclerosis; For hardening plaques, the proportion of the main cardiovascular events in patients decreased by 41.7%, especially in the incidence of unstable angina pectoris by 41.8%. The research papers were published in the Science Report, which influenced factors of 4.38.

The "Jinlida Unite Two Double Two Double -Demo Treatment Type 2 Diabetes Random, Double Blinds, Place Control, Multi -Center Clinical Research" carried out by the "Jinlida Unite Two Double Pyramid" was led by the Guang'anmen Hospital of the Chinese Academy of Traditional Chinese Medicine. ; Reduce the waist circumference, reduce the weight index, significantly improve the symptoms of thirst and constipation; improve insulin resistance, improve insulin sensitivity and β cell function index; have potential treatment advantages for delaying chronic complications of diabetes; Advantage. The two -metal dual -tadpole combined Jinlida particles significantly reduce glycated hemoglobin. The research papers are published in the Public Science Library · Comprehensive Journal, with the influencing factors of 3.24.

In 2009, Lianhua Qing Plague Capsule was randomly dual -blind, multi -center and Osdowei in the treatment of clinical research on the treatment of H1N1 Influenza. It was completed by Ya'an Hospital affiliated to the Capital Medical University and 8 hospitals. The research papers were published in the "Chinese Medical Magazine", which is 2.628 in the magazine.

In 2020, Lianhua Qing Plague treatment of new crown pneumonia's forward -looking, random, control, multi -center clinical research, was completed by 23 hospitals in 9 provinces in Wuhan University People's Hospital. The disappearance rate of clinical symptoms (fever, fatigue, cough) (91.5 % vs.82.4 %), CT improvement rate (83.8 % vs.64.1 %), and clinical cure rate (78.9 % vs.66.2 %), and clinical cure rates (fever, fatigue, fatigue, cough). The reduction rate of 50%shows a good trend. The results of the research are published in the world -renowned "PHYTOMEDICINE" journal, which is 5.34 in the magazine.

It is believed that insisting on using modern science to prove the efficacy of traditional Chinese medicine, it will promote the high -quality development of the Chinese medicine industry!

- END -